VAV3 mediates resistance to breast cancer endocrine therapy. - Wikidata - awgldk - TriplyDB

VAV3 mediates resistance to breast cancer endocrine therapy.

VAV3 mediates resistance to breast cancer endocrine therapy.

http://www.wikidata.org/entity/Q33827037

about

Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization.Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.The Rac GTPase in Cancer: From Old Concepts to New Paradigms.The clinical value of Vav3 in peripheral blood for predicting lymphatic metastasis of gastric cancer.Evaluation of Vav3.1 as prognostic marker in endometrial cancer

P2860

Q26782144-18E105AD-0D9E-4AF8-B29E-3DB6FD4C06D0 Q33821469-33116500-70C4-49B4-A8B4-5A2ECFD30677 Q35643021-C51A9478-A618-4BFF-90B7-54C3277029D7 Q36067934-76C54E06-51CD-49F0-8C04-1B7527D0ADA9 Q38920711-941A885D-6B9D-4C32-87D2-465C340CF28E Q47953335-E397368A-8356-49BA-8D1E-D22E50077850 Q50997022-3123A85F-083D-4F70-8C17-16DADB906878 Q57141071-04CEFEC6-6230-4BAB-808C-661CD1DA5B05

P2860

VAV3 mediates resistance to breast cancer endocrine therapy.

http://www.wikidata.org/entity/Q33827037

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

VAV3 mediates resistance to breast cancer endocrine therapy.

@ast

VAV3 mediates resistance to breast cancer endocrine therapy.

@en

type

label

VAV3 mediates resistance to breast cancer endocrine therapy.

@ast

VAV3 mediates resistance to breast cancer endocrine therapy.

@en

prefLabel

VAV3 mediates resistance to breast cancer endocrine therapy.

@ast

VAV3 mediates resistance to breast cancer endocrine therapy.

@en

P1433

Q33827037-3593633B-A3B0-4F59-AE3E-C8D0091B2BD5

P1476

Q33827037-4A9D197A-2C9A-4DCF-95F0-004E18128870

P2093

Q33827037-079E543E-10AD-4F47-AD35-720CF14ED1E7

Q33827037-0845F6F6-4173-474B-8299-AAC59DC0A9D4

Q33827037-0CD55043-5277-4575-B954-4B9F8DA915B2

Q33827037-0EAD48BD-FC34-4B45-80A0-07A805F7130D

Q33827037-1DA70330-C50E-4E31-9B3F-99F9EB283B2F

Q33827037-20CAD231-76F5-493F-A0CF-70CA1F98EC5F

Q33827037-269F5D27-069A-477D-B293-DFCC504799A3

Q33827037-39C3906A-0C3B-4357-854E-5D4B5FF11519

Q33827037-3EFC6BCB-BDB9-423D-B532-ADBD78873171

Q33827037-461512A1-D0E2-46F8-9F0D-C6BD4D5ACEE3

P2860

Q33827037-01715C00-28FD-4306-9F80-297DAADF45F5

Q33827037-03CB44CE-C17D-4FA0-B418-C0C074B61AB5

Q33827037-0BA646EC-6050-4069-B0FF-3E8C2327C585

Q33827037-14879A89-B444-4588-8BDE-69702C0CC3E6

Q33827037-1584F00D-E8A7-40B3-A562-248183AE257A

Q33827037-253D34C3-AEAD-4600-88C1-5DA211C46D06

Q33827037-28627F45-4F7E-4248-AA71-7D569067F9D4

Q33827037-291C9642-E337-4CF4-91C1-6652E66BBDB4

Q33827037-2FDE7385-66F1-4293-A03A-5A58ED84C242

Q33827037-40CE2788-1500-4AEE-BB58-6D158F2D0580

P2888

Q33827037-76FE2E93-842C-482D-B138-98EEAF26DB7E

P304

Q33827037-04D864B5-19EF-4985-9FAF-CC9BC42635C8

P31

Q33827037-4D2CAE1E-F1E7-4928-9764-195934F9F53B

P356

Q33827037-BC768EFA-C600-4ACD-B507-90B39CAD5239

P433

Q33827037-04DA1A1A-7451-4E74-9640-1C14CD86F633

P478

Q33827037-0C88BAFE-336D-40F9-A257-10FA507F0522

P50

Q33827037-01DF7DD5-E9B2-4AEB-8784-30805AEE917C

Q33827037-0FBA0DA5-D079-4C58-83FF-0076CB4E01BA

Q33827037-30543333-DE3E-4D92-829A-38B2B4074C94

Q33827037-563BF802-402B-46D6-A55E-227B9D16E174

Q33827037-7130990E-50F2-48BE-8E44-DFE715316B7C

Q33827037-7CC9E855-0BC7-46C8-95D6-A381E8BA4D9A

Q33827037-AAB8645A-ED00-4B9C-9728-5E1F17FBE75D

Q33827037-AE5FA52A-9EA1-429B-98A4-BCF9097EC2E5

Q33827037-B574C063-3523-4BA0-99BC-26235C31911B

Q33827037-F2468F5D-A4DF-4BC3-8B7B-817AD037E2E5

P577

Q33827037-3A67453C-8AD9-4A32-B21E-F7D93177EF66

P5875

Q33827037-B4269496-F614-4E19-B6AA-AEDBCADA6462

P6179

Q33827037-A6431101-15CD-4E50-A7BE-E36618677FDF

P698

Q33827037-4D94DDC6-9B4A-491C-A979-66313358AEBB

P932

Q33827037-296EC631-88DB-445F-9477-B7A95A0FDE2A

P356

P1433

Breast Cancer Research

P1476

VAV3 mediates resistance to breast cancer endocrine therapy

@en

P2093

Abul Islam

http://www.w3.org/2001/XMLSchema#string

Agnes Figueras

http://www.w3.org/2001/XMLSchema#string

Alberto Villanueva

http://www.w3.org/2001/XMLSchema#string

Alejo Rodríguez-Vida

http://www.w3.org/2001/XMLSchema#string

Ana B Rodríguez-Peña

http://www.w3.org/2001/XMLSchema#string

Dennis C Sgroi

http://www.w3.org/2001/XMLSchema#string

Ekaterina Nevedomskaya

http://www.w3.org/2001/XMLSchema#string

Elin Karlsson

http://www.w3.org/2001/XMLSchema#string

Gizeh Pérez Tenorio

http://www.w3.org/2001/XMLSchema#string

Griselda Martrat

http://www.w3.org/2001/XMLSchema#string

P2860

Model-based analysis of ChIP-Seq (MACS)

Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation.

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities

Coupling of receptor conformation and ligand orientation determine graded activity

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

P2888

P304

R53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR3664

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Luciano Di Croce

Xosé R. Bustelo

Ander Urruticoechea

Ana I Extremera

P577

2014-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262764180

http://www.w3.org/2001/XMLSchema#string

P6179

1015256203

http://www.w3.org/2001/XMLSchema#string

P698

24886537

http://www.w3.org/2001/XMLSchema#string

P932

4076632

http://www.w3.org/2001/XMLSchema#string